{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-21-097603","form_type":"8-K","ticker":"SUPN","cik":"0001356576","company_name":"SUPERNUS PHARMACEUTICALS, INC.","filed_at":"2021-07-29T23:59:59+00:00","discovered_at":"2026-05-14T18:04:17.815099+00:00","generated_at":"2026-06-30T00:53:19.361927+00:00","sec_items":["5.02","9.01"],"event_type":"leadership","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"SUPN CFO James P. Kelly resigns; Timothy C. Dec appointed as new CFO","bullets":["James P. Kelly resigns as EVP & CFO effective August 13, 2021 to join another company.","Timothy C. Dec appointed SVP & CFO effective August 23, 2021; over 35 years experience, most recently CFO of OpGen.","Dec receives $375,000 annual base salary, 40% target bonus prorated first year, and 85,000 options vesting over 4 years.","Dec enters Executive Retention Agreement with severance payments and accelerated vesting upon change in control."],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-21-097603","json":"https://secwatch.observer/filing/0001104659-21-097603.json","markdown":"https://secwatch.observer/filing/0001104659-21-097603.md","text":"https://secwatch.observer/filing/0001104659-21-097603.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1356576/000110465921097603/0001104659-21-097603-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1356576/000110465921097603/tm2123591d1_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-30T00:53:19.361927+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"4bcf732c19","claim":"James P. Kelly resigned as Executive Vice-President and Chief Financial Officer at SUPERNUS PHARMACEUTICALS, INC..","evidence_excerpt":"On July 23, 2021, James P. Kelly, Executive Vice-President and Chief Financial Officer, notified Supernus Pharmaceuticals, Inc. (“Supernus” or the “Company”) of his resignation from the Company to join another company.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1356576/000110465921097603/0001104659-21-097603-index.htm","confidence":1.0,"family_label":"Executive change","details":[{"label":"Action","value":"resigned"},{"label":"Role","value":"Executive Vice-President and Chief Financial Officer"}],"fact_type":"executive_change"},{"claim_id":"61823fd887","claim":"Timothy C. Dec was appointed as Senior Vice-President and Chief Financial Officer at SUPERNUS PHARMACEUTICALS, INC..","evidence_excerpt":"On July 27, 2021, the Company appointed Timothy C. Dec to the position of Senior Vice-President and Chief Financial Officer.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1356576/000110465921097603/0001104659-21-097603-index.htm","confidence":1.0,"family_label":"Executive change","details":[{"label":"Action","value":"appointed"},{"label":"Role","value":"Senior Vice-President and Chief Financial Officer"}],"fact_type":"executive_change"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}